Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) was up 4.7% on Thursday . The stock traded as high as $18.12 and last traded at $18.12. Approximately 39,716 shares changed hands during mid-day trading, a decline of 81% from the average daily volume of 214,132 shares. The stock had previously closed at $17.30. Analyst Ratings […]
Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) was up 4.7% on Thursday . The stock traded as high as $18.12 and last traded at $18.12. Approximately 39,716 shares changed hands during mid-day trading, a decline of 81% from the average daily volume of 214,132 shares. The stock had previously closed at $17.30. Analyst Ratings […]
Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) Director Richard A. Heyman sold 1,270 shares of the firm’s stock in a transaction on Tuesday, January 30th. The stock was sold at an average price of $16.41, for a total value of $20,840.70. Following the completion of the sale, the director now directly owns 146,010 shares […]
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Rating) CFO Keith A. Goldan sold 577 shares of the business’s stock in a transaction on Tuesday, June 13th. The stock was sold at an average price of $22.31, for a total value of $12,872.87. Following the transaction, the chief financial officer now owns 2,628 shares of the company’s […]
HealthCor Management L.P. lowered its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Rating) by 91.9% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 70,000 shares of the company’s stock after selling 789,240 shares during the period. Syndax Pharmaceuticals makes up about […]